TFBS Bioscience Inc (6939) Fair Value & Analysis
Healthcare · TW · Market cap 720M TWD
Fair value as of: Jul 23, 2026
From 3 valuation models · updated 13 days ago
Fair value updated Jul 23, 2026, revised from 20.86 TWD to 21.05 TWD (+0.9%) since Jul 12, 2026. Share price −1.5% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (12.63 TWD to 30.44 TWD) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
39‑month range 18.80 TWD – 71.12 TWD · fair‑value band 12.63 TWD – 30.44 TWD · the 19.40 TWD price screens below the 21.05 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
TFBS Bioscience Inc (6939) currently trades at 19.40 TWD, while our model-based Fair Value estimate is 21.05 TWD, implying the stock looks roughly 8.5% fairly valued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
The balance sheet holds a net cash position of 320M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 12.63 TWD (bear case) to 30.44 TWD (bull case); at 19.40 TWD, the current price sits within that range. The share trades about 34% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at 9%, 6939 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (721.21 TWD) versus Dividend Discount (17.81 TWD). Highest evidence: Gordon GGM (70).
Key figures & financial health
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 37 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.
Full company description
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TFBS Bioscience Inc reported revenue of 193M TWD in FY2025 versus 161M TWD in FY2021, a compound +4.7%/yr. Reported net income was −74.5M TWD in FY2025.
Watch 6939: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 140 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.05 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare TFBS Bioscience Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TFBS Bioscience Inc (6939) overvalued or undervalued?
What is the fair value of 6939?
What is the quality score of 6939?
What is the net profit margin of 6939?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track TFBS Bioscience Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.